The Inhibitory Effect of Down-Regulating Phosphorylated HER2 on Proliferation and Metastasis in U2-OS Osteosarcoma Cells
10.3969/j.issn.0253-9896.2014.01.001
- VernacularTitle:下调HER2磷酸化水平对骨肉瘤细胞U2-OS体外增殖转移的抑制作用研究
- Author:
Zhihong ZHANG
;
Xinhua LONG
;
Zhili LIU
;
Heng WANG
;
Taofang WANG
;
Liangbo ZHU
- Publication Type:Journal Article
- Keywords:
receptor,epidermal growth factor;
oxidative phosphorylation;
osteosarcoma;
cell proliferation;
neoplasm invasiveness;
lapatinib ditosylate;
U2-OS
- From:
Tianjin Medical Journal
2014;(1):1-3,4
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of down-regulating phosphorylated human epidermal growth factor receptor 2 (HER2) on the proliferation and metastasis in human osteosarcoma cells (U2-OS) in vitro. Methods Various concentrations of HER2 phosphorylation inhibitor lapatinib ditosylate (5, 10, 20, 30 and 40 μmol/L) were adopted to deal with U2-OS. MTT assay was performed to evaluate the cell proliferation during various times (24, 48 and 72 h), and the IC50 value in 24 h was calculated. The value of 10μmol/L (IC50=22.15μmol/L) was chosen to deal with U2-OS cells. The expres-sion level of phosphorylated HER2 (p-HER2) was measured by Western blot assay. The cell migration and invasion abilities were detected by Wound healing and Transwell invasion assays. Results The cell proliferation of U2-OS was significantly inhibited by HER2 phosphorylation inhibitor lapatinib ditosylate in a concentration- and time-dependent manner. During 24 hours, the p-HER2 level was significantly lower in lapatinib ditosylate group than that of negative control group (0.093± 0.033 vs 0.306±0.033), the cell migration rate was significantly lower in lapatinib ditosylate group than that of negative con-trol group (32.70%±3.00%and 94.52%±4.76%), and the trans-membrane cells were significantly lower than those of nega-tive control group (37/HP±5/HP and 85/HP±10/HP), respectively. Conclusion The down-regulating p-HER2 in U2-OS could efficiently inhibit the cell proliferation, migration and invasion in vitro. HER2 has the potential to become a molecular target for anti-osteosarcoma metastasis.
